Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04545333 · ClinicalTrials.gov registry record
The clonoSEQ® Watch Registry
A clinical trial, sponsored by Adaptive Biotechnologies.
- Terminated
- Registry status
- 465
- Enrollment target
NCT04545333: Clinical Trial study, sponsored by Adaptive Biotechnologies.
NCT04545333 is a clinical trial that was terminated before completion, run by Adaptive Biotechnologies. The registered enrollment target is 465 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04545333 was terminated before completion, sponsored by Adaptive Biotechnologies.
- TERMINATED
- Registry status
- 465 participants
- Enrollment target
Study Summary
This is a prospective, multicenter, observational study of adult patients with a diagnosis of acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), or non-Hodgkin lymphoma (NHL). This study will enroll up to 528 patients in up to 50 sites in the United States and collect data with regard to use of the clonoSEQ MRD assay in the management of lymphoid malignancies.
Primary Outcome
Data will be collected to determine at what points lymphoid malignancy patients are in their treatment continuums when the clonoSEQ Assay is used to monitor MRD levels
Interventions
- DIAGNOSTIC_TEST clonoSEQ Assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 465 participants |
| Start Date | 2020-10-13 |
| Est. Completion | 2023-10-01 |
Why NCT04545333 stopped before completion
NCT04545333 is an observational study that tracks outcomes without assigning an intervention. The registered 465 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which clonoSEQ Assay is the first listed.
NCT04545333 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04545333 about?
NCT04545333 is a clinical study titled "The clonoSEQ® Watch Registry". This is a prospective, multicenter, observational study of adult patients with a diagnosis of acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), or non-Hodgkin lymphoma (NHL). This study will enroll up to 528 patients in up to 50 sites in the United States...
What is the current status of trial NCT04545333?
This trial is currently terminated. The enrollment target is 465 participants. The study started on 2020-10-13. Estimated completion is 2023-10-01.
What interventions are being tested in trial NCT04545333?
The interventions under investigation include: clonoSEQ Assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04545333?
This trial is sponsored by Adaptive Biotechnologies, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06717698 · 465 participants · Phase 2
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
- NCT07420283 · 465 participants · Phase 2
A Study of Brenipatide in Participants With Opioid Use Disorder
- NCT05312879 · 466 participants · Phase 2
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
- NCT06917404 · 466 participants · Phase 3
A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI